Publications by authors named "L Baylis"
Background And Aims: Real-world evidence characterising the burden of eosinophilic granulomatosis with polyangiitis (EGPA) in Europe is limited. The aim of this study was to characterise patients in a large European EGPA cohort.
Methods: This retrospective, non-interventional, longitudinal study (GSK ID: 214661) recruited cross-specialty physicians from France, Germany, Italy, Spain and the UK to conduct medical chart reviews for patients with a physician-confirmed diagnosis of EGPA.
Article Synopsis
- The MERIT study was a 52-week Phase III clinical trial that evaluated the efficacy and safety of mepolizumab for treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in Japan, Russia, and China.
- Mepolizumab significantly improved nasal obstruction scores in patients compared to placebo, with some improvement seen in nasal polyp scores, and had a manageable safety profile with few serious adverse events.
- The findings suggest that mepolizumab is an effective treatment option for patients suffering from CRSwNP/ECRS in these regions.
Background: The Mepolizumab in Relapsing or Refractory EGPA (MIRRA) trial (GSK ID: 115921/NCT02020889) demonstrated that mepolizumab increased remission time and reduced oral corticosteroid (OCS) use compared with placebo in patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The present analysis investigated the impact of baseline characteristics on clinical outcomes and characterised the OCS-sparing effect of mepolizumab.
Methods: In a phase 3, randomised controlled trial for patients with EGPA (MIRRA), patients received standard of care plus mepolizumab 300 mg or placebo every 4 weeks for 52 weeks.
Objective: To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype.
Methods: The MIRRA study (NCT02020889/GSK ID: 115921) included adults with relapsing/refractory EGPA and 4 or more weeks of stable oral glucocorticoids (OG). Patients received mepolizumab (300 mg subcutaneously every 4 weeks) or placebo, plus standard of care for 52 weeks.
Article Synopsis
- - Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) share symptoms and elevated eosinophil counts, but their underlying mechanisms and diagnostic guidelines are poorly understood.
- - The causes of most HES cases are unknown, while EGPA has some identified genetic risks, yet clear pathogenic mechanisms and reliable disease markers are lacking for both conditions.
- - Current diagnostic criteria are difficult for general practitioners to apply, and there's a need for better disease activity scores and biomarkers to improve treatment assessment and patient management.